A multicenter phase II clinical trial has demonstrated that a chemotherapy regimen combining nab-paclitaxel with cisplatin delivers superior efficacy compared to gemcitabine in treating advanced biliary tract cancer. The study, published in BMC Cancer, indicates improved therapeutic outcomes with manageable safety profiles, offering a promising alternative for this challenging malignancy.